Adiso
Advancing Novel Therapies for Inflammatory Diseases
Adiso creates medicines to treat inflammatory diseases, to improve the lives of patients and their families with an innovative pipeline of small molecules (neutrophil modulation, inflammasome inhibition) and single strain live biotherapeutic products (SS-LBP), all with novel mechanisms of action.
Apellis
Targeting the Complement Pathway in Innate Immunity
Complement-mediated disorders stem from overactive innate immune activity. Apellis is developing an injectable peptide therapy that inhibits the C3 complement protein in diseases like paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, geographic atrophy of the eye, and cold agglutinin disease. C3 inhibition reduces the severity of symptoms that C5 inhibition does not affect.
Apellis recently announced positive Phase 3 data in PNH and are looking to advance trials in many other complement disorders.
Biothea
Revolutionizing the Treatment of Severe Allergic Reactions and Anaphylaxis
Anaphylaxis, also called allergic or anaphylactic shock, is a sudden, severe and life-threatening allergic reaction. Biothea is focused on revolutionizing the treatment of severe allergic reactions and anaphylaxis by providing needle-free, convenient and cost effective alternative to currently available products.
Canopy Immuno-Therapeutics
Creating Non-Immunosuppressive Biologics to Potentially Cure Autoimmune Disease
Canopy Immuno-Therapeutics is developing a novel class of antigen-specific biologics through its “Reverse Immunization” platform with the goal of eliminating pathogenic immune responses in autoimmune disorders and severe allergies, without broadly suppressing the immune system.
canopy-biotech.com
Neutrolis
Targeting the Dark Side of DNA
Neutrolis is developing first-in-class therapies for autoimmune and inflammatory diseases by targeting Neutrophil Extracellular Traps (NETs), a fundamental arm of the innate immune system which plays an important role in chronic and acute diseases. Neutrolis employs the exDNASE platform, based on naturally occurring enzymes that degrade the extracellular chromatin that form NETs, and powers the creation of natural and engineered enzyme analogs that are capable of treating several acute and chronic unmet medical needs.
The lead candidate NTR-441 is an enhanced analog of DNASE1L3, an enzyme produced by immune cells that degrades NETs into biologically inactive fragments to attenuate a severe immune response. The company’s pipeline includes NTR-441, systemically active engineered DNASE1L3, and NTR-452, locally active engineered DNASE1L3, that effectively removes NETs and halt their pathologic effects.